Cargando…

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma

The endocrine secretions of carcinomas can be life-threatening. Medullary thyroid carcinoma (MTC) is a rare cancer that is often associated with cortisol secretion, leading to paraneoplastic Cushing’s syndrome. Mutations of the proto-oncogene RET are driver molecular events in 70% of MTC cases. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sitbon, Marine, Chou, Porhuoy, Bengaly, Seydou, Poirot, Brigitte, Laloi-Michelin, Marie, Deville, Laure, Pachev, Atanas, Kowo-Bille, Ahouefa, Dumont, Clement, Chougnet, Cécile N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578062/ https://www.ncbi.nlm.nih.gov/pubmed/36069795 http://dx.doi.org/10.1530/ETJ-22-0032

Ejemplares similares

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
por: Ragnarsson, Oskar, et al.
Publicado: (2022)

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib
por: Turin, Christie Gloria, et al.
Publicado: (2021)

Sporadic Medullary Thyroid Carcinoma with Paraneoplastic Cushing Syndrome
por: Pivovarova, Aleksandra I., et al.
Publicado: (2019)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
por: Bardet, Stéphane, et al.
Publicado: (2022)

Simultaneous ectopic adrenocorticotropic hormone syndrome and adrenal metastasis of a medullary thyroid carcinoma causing paraneoplastic Cushing's syndrome
por: Sand, Michael, et al.
Publicado: (2007)

FRI355 Hypokalemia-induced Nephrogenic Diabetes Insipidus In A Patient With Medullary Thyroid Carcinoma And Paraneoplastic Cushing’s Syndrome
por: Jhawar, Sakshi, et al.
Publicado: (2023)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Paraneoplastic Cushing Syndrome in Gastrointestinal Neuroendocrine Tumour
por: Mineur, Laurent, et al.
Publicado: (2021)

Correction to: Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

PSAT387 An Unusual Case of Sporadic Metastatic Medullary Thyroid Cancer Without a Primary Tumor Presenting with Paraneoplastic Cushing's Syndrome
por: Jumani, Sanjay, et al.
Publicado: (2022)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

An Aggressive Case of Adrenocortical Carcinoma Complicated by Paraneoplastic Cushing’s Syndrome
por: Mohamed Jiffry, Mohamed Zakee, et al.
Publicado: (2023)

Metastatic medullary thyroid carcinoma presenting as ectopic Cushing’s syndrome
por: Forde, Hannah E, et al.
Publicado: (2021)

Case-series of paraneoplastic Cushing syndrome in small-cell lung cancer
por: Richa, Carine Ghassan, et al.
Publicado: (2018)

A Case of Paraneoplastic Erythropoietin Secretion Secondary to Medullary Thyroid Cancer
por: Pare, Aurelie, et al.
Publicado: (2021)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
por: Baek, Han-Sang, et al.
Publicado: (2023)

ODP477 Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer
por: Mateen, Abdul, et al.
Publicado: (2022)

Peripheral primitive neuroectodermal tumor associated with paraneoplastic Cushing's syndrome: The rare case
por: Rahbar, Mahtab, et al.
Publicado: (2018)

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome
por: Brzezniak, Christina E., et al.
Publicado: (2017)

The importance of recognizing paraneoplastic symptoms: a case report of Neuroendocrine Small Cell Carcinoma of the Endometrium presenting as Paraneoplastic Cushing’s Syndrome.
por: Doukhopelnikoff, A, et al.
Publicado: (2017)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Kinase inhibitors for advanced medullary thyroid carcinoma
por: Schlumberger, Martin, et al.
Publicado: (2012)

Case report of severe Cushing’s syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentration
por: Hammami, Muhammad M., et al.
Publicado: (2015)

Cushing's syndrome as a paraneoplastic feature of renal cell carcinoma: A case report
por: Moradi, Asaad, et al.
Publicado: (2023)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

LBODP064 A Rare Case Of Paraneoplastic Cushing Syndrome Associated With Pulmonary Carcinoid Tumor
por: Mandal, Gaurav, et al.
Publicado: (2022)

Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
por: Dormoy, Alexandre, et al.
Publicado: (2022)

Epidemiology, Risk Factors and Diagnosis of Small Bowel Adenocarcinoma
por: Aparicio, Thomas, et al.
Publicado: (2022)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Paraneoplastic Cushing's syndrome and hypercalcemia arising from metastatic endometrioid endometrial adenocarcinoma: A case report
por: Mitchell, Evelyn, et al.
Publicado: (2019)

Paraneoplastic Cushing's syndrome associated with bronchopulmonary carcinoid tumor in youth: A case report and review of the literature
por: LI, WEN-YA, et al.
Publicado: (2016)

Management of small cell lung cancer complicated with paraneoplastic Cushing’s syndrome: a systematic literature review
por: Li, Yanlong, et al.
Publicado: (2023)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib
por: Al-Zaqri, Nabil, et al.
Publicado: (2021)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o8c28ndkse7tcmr6jlm4odq6vf